Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by Str8Shuteron Sep 16, 2020 8:09pm
123 Views
Post# 31572096

RE:Boston Strong

RE:Boston StrongFollowing are some excerpts directly related to Mass General from the unofficial 4Q2019 transcript that was posted on Seeking Alpha at the time.  I do not see any references to Harvard though:

https://seekingalpha.com/article/4348864-stagezero-life-sciences-gnwsf-ceo-james-howard-tripp-on-q4-2019-results-earnings-call

Slide four please.  So, 2021.  I think as we've looked at it -- and I was part of a discussion group about a week ago tied into Mass General, where they were talking about things right now.  And for example, about 90% of the hospitals are closed; the 10% of the hospitals that are open are focused very heavily into COVID.  You look at how they get to begin to bring patients in for surgery and they say even as they come in, you're going to have to test absolutely -- you're going to be negative or you're going to have to show the antibodies you've had it, but you're virus-free.
...
If I just stay with the Mass General for a moment, in December of last year, approximately 1% of their interaction with patients was by what they called Virtual Care.  Right now, it's 85% of what they do.  We had discussion about how much they expected to settle back and general opinion was it'll settle back probably to about 40% to 50%.  But what we've seen is an absolute sea change in how things are done.
...
Slide 11, market opportunity for our blood tests as we laid out is no different.  We're focusing on physician practices; that will always be part of what we do.  However, we're very clearly focused into patient directed testing. And go back to my discussion about Mass General earlier.  It's becoming much more a patient-centric healthcare model as we move forward the patient much more in the driving seat, a lot more of it being done from the comfort of their homes.  And so you have to be able to cater to this.  This is where our two-year build out is really coming to bear.
...
It's going to open up again, but again, the learner group at Mass General was talking about everyone fully expects a second peak in November-December.  Everyone's desperately hoping that there isn't a third or fourth peak between now and November-December as we actually open up.

 

BOLTA


Nailbiter1 wrote:

I can't help going back to what the CEO mentioned in one of his conference calls.

Peer brought it to my attention and now I blame him for the guns in my head.

"Harvard" and "Mass Gen" came up. I wish I had access to the Q4-2019 or Q1, Q2
"seeking alpha" transcripts.

If we are using the prestigious Harvard Massachusetts General Hospital

(with one of the world's most renowned cancer centres)

to finalize Aristotle, it would be great news indeed.

Mass Gen is the country's #1 research hospital.

They would be the ones to best expedite Aristotle.

Of course, I'm speculating on some loose dot connections.

James is as tight as a camel's aresole in a sand storm.

Any bit of news on covid updates or Aristotle advancements could get us to
at least .10 cents to slam the RS.

(snip, snip...)


Bullboard Posts